FDA Evaluation of Pathogen Reduction Technologies & Noncoding Regulatory RNAs in Blood Components
*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available in the Office of Blood Research and Review (OBRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The laboratory's research focus is on identifying and evaluating pathogen inactivation methods relevant to stored blood and blood components' safety and microRNA based biomarker development for product quality.
Under the guidance of a mentor, the participant will be involved in the following research activities:
- Screening novel methods and reagents for pathogen inactivation in blood and blood components (platelets, red blood cells and plasma).
- Evaluating the effect of such treatments on the survival and function of platelets and red blood cells and plasma.
- Evaluating the treated plasma for the activities of coagulation factors.
- Mitigating the adverse effects (if any) of the treatments
- Developing biomarkers of product quality following pathogen inactivation treatments.
Anticipated Appointment Start Date: January 10, 2021
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2021-0001) in your email.